A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer

被引：4

作者：

Taira, Yusuke ^{[1
]}

Shimoji, Yuko ^{[1
]}

Nakasone, Tadaharu ^{[1
]}

Arakaki, Yoshihisa ^{[1
]}

Nakamoto, Tomoko ^{[1
]}

Kudaka, Wataru ^{[1
]}

Aoki, Yoichi ^{[1
]}

机构：

[1] Univ Ryukyus, Grad Sch Med Sci, Obstet & Gynecol, Uehara 207,Nishihara Town, Okinawa 9030125, Japan

来源：

JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH | 2021年 / 47卷 / 02期

关键词：

bevacizumab; cervical cancer; nasal septal perforation; ENDOTHELIAL GROWTH-FACTOR; TREATED PATIENT;

D O I：

10.1111/jog.14589

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Nasal septal perforation caused by bevacizumab is rarely reported in other cancers such as ovarian cancer and breast cancer, but it has not been reported in cervical cancer. A 48-year-old woman with a medical history of chronic allergic rhinitis was diagnosed stage 4B (T2bN1M0) cervical cancer and paclitaxel and carboplatin along with bevacizumab (triweekly) were administered. After eight courses of chemotherapy, nasal septal perforation was noted. The possibility of nasal septal perforation by bevacizumab was considered by excluding other causes. We report the first case of nasal septal perforation caused by bevacizumab for advanced cervical cancer.

引用

收藏

页码：833 / 837

页数：5

相关论文

共 22 条

[1] Cellular abnormalities of blood vessels as targets in cancer [J].

Baluk, P ;

Hashizume, H ;

McDonald, DM .

CURRENT OPINION IN GENETICS & DEVELOPMENT, 2005, 15 (01) :102-111

[2] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer [J].

Burger, Robert A. ;

Brady, Mark F. ;

Bookman, Michael A. ;

Fleming, Gini F. ;

Monk, Bradley J. ;

Huang, Helen ;

Mannel, Robert S. ;

Homesley, Howard D. ;

Fowler, Jeffrey ;

Greer, Benjamin E. ;

Boente, Matthew ;

Birrer, Michael J. ;

Liang, Sharon X. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2473-2483

[3] Spontaneous Nasal Septal Perforation With Antiangiogenic Bevacizumab Therapy [J].

Burkart, Collin M. ;

Grisel, Jedidiah J. ;

Hom, David B. .

LARYNGOSCOPE, 2008, 118 (09) :1539-1541

[4] Perforation of the nasal septum: A rare complication of bevacizumab [J].

Bylicki, O. ;

Boursier, C. ;

Peloni, J. -M. ;

Dot, J. -M. .

REVUE DES MALADIES RESPIRATOIRES, 2012, 29 (09) :1124-1126

[5] Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer [J].

Chambers, Setsuko K. ;

Clouser, Mary C. ;

Baker, Amanda F. ;

Roe, Denise J. ;

Cui, Haiyan ;

Brewer, Molly A. ;

Hatch, Kenneth D. ;

Gordon, Michael S. ;

Janicek, Mike F. ;

Isaacs, Jeffrey D. ;

Gordon, Alan N. ;

Nagle, Raymond B. ;

Wright, Heather M. ;

Cohen, Janice L. ;

Alberts, David S. .

CLINICAL CANCER RESEARCH, 2010, 16 (21) :5320-5328

[6] An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab [J].

D'Amico, Mauro ;

Pagano, Mauro ;

Pasa, Ambra ;

Puntoni, Matteo ;

Clavarezza, Matteo ;

Gennari, Alessandra ;

Gozza, Alberto ;

Zanardi, Silvia ;

Defferrari, Carlotta ;

Provinciali, Nicoletta ;

Campazzi, Eleonora ;

Campora, Sara ;

Paleari, Laura ;

Marra, Domenico ;

Petrera, Marilena ;

DeCensi, Andrea .

EXPERT OPINION ON DRUG SAFETY, 2014, 13 (11) :1437-1442

[7] Bevacizumab-induced nasal septum perforation [J].

Fakih, Marwan G. ;

Lombardo, Jeffrey C. .

ONCOLOGIST, 2006, 11 (01) :85-86

[8] Nasal septal perforation secondary to systemic bevacizumab [J].

Geltzeiler, Mathew ;

Steele, Toby O. .

AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2017, 38 (03) :354-355

[9] Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence [J].

Hanna, Ramy M. ;

Barsoum, Marina ;

Arman, Farid ;

Selamet, Umut ;

Hasnain, Huma ;

Kurtz, Ira .

KIDNEY INTERNATIONAL, 2019, 96 (03) :572-580

[10] Bevacizumab-induced hypertension: Clinical presentation and molecular understanding [J].

Li, Megan ;

Kroetz, Deanna L. .

PHARMACOLOGY & THERAPEUTICS, 2018, 182 :152-160